Skip to main content
Atrás
Watch Compare

AVENUE THERAPEUTICS, INC.

Calidad de datos: 100%
ATXI
OTC Manufacturing Chemicals
$0.45
▲ $0.10 (28.57%)
Cap. Mercado: 1.48 M
Precio
$0.45
Cap. Mercado
1.48 M
Rango del Día
$0.45 — $0.45
Rango de 52 Semanas
$0.15 — $0.97
Volumen
2,937
Apertura $0.45
Promedio 50D / 200D
$0.24
91.00% above
Promedio 50D / 200D
$0.54
16.85% below

Quick Summary

Puntos Clave

Negative free cash flow of -1.83 M

Crecimiento

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
-76.40%
Below sector avg (-51.02%)
ROIC-94.86%
Net Margin-207.19%
Op. Margin-219.59%

Seguridad

Debt / Equity
N/A
Current RatioN/A
Interest CoverageN/A

Valoración

PE (TTM)
-0.51
Above sector avg (-1.98)
P/B Ratio0.42
EV/EBITDAN/A
Dividend YieldN/A

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Manufacturing (44 pares)
Métrica Acción Mediana del Sector
P/E -0.5 -2.0
P/B 0.4 5.1
ROE % -76.4 -51.0
Net Margin % -207.2 -150.2
Rev Growth 5Y % — 9.3
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1.40 M Net Income (TTM) -2.91 M
ROE -76.40% ROA -73.78%
Gross Margin N/A Operating Margin -219.59%
Net Margin -207.19% Free Cash Flow (TTM) -1.83 M
ROIC -94.86% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio N/A
Interest Coverage N/A Asset Turnover 0.36
Working Capital N/A Tangible Book Value 3.56 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.51 Forward P/E N/A
P/B Ratio 0.42 P/S Ratio 1.06
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -123.64%
Market Cap 1.48 M Enterprise Value -2.23 M
Per Share
EPS (Diluted TTM) N/A Revenue / Share 0.43
FCF / Share -0.56 OCF / Share -0.56
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 63.01%
SBC-Adj. FCF -2.69 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1.40 M — — — —
Net Income -2.91 M -11.70 M -10.49 M -3.55 M -3.73 M
EPS (Diluted) — — — — -0.22
Gross Profit — — — — —
Operating Income -3.08 M -11.28 M -14.54 M -8.04 M -3.74 M
EBITDA — — — — —
R&D Expenses 1.04 M 6.65 M 6.13 M 2.70 M 1.25 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense — — — — —
Income Tax 2,000.0 0.0 0.0 — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 2.93 M 2.67 M 1.85 M 6.85 M 3.96 M
Total Liabilities 1.10 M 816,000.0 1.20 M 3.58 M 509,000.0
Shareholders' Equity 1.83 M 2.80 M 1.58 M 3.91 M 3.45 M
Total Debt — — — — —
Cash & Equivalents 2.86 M 2.59 M 1.78 M 6.71 M 3.76 M
Current Assets — — — — 3.96 M
Current Liabilities 1.10 M 816,000.0 1.20 M 3.58 M 509,000.0